Who is sponsoring MEMENTO?

MEMENTO is sponsored by Tata Memorial Centre.

What condition does MEMENTO study?

MEMENTO studies Neurocognitive Dysfunction.

What drugs are being tested in MEMENTO?

Interventions: Memantine Oral Tablet.

What is the status of MEMENTO?

MEMENTO is currently RECRUITING.

Last reviewed 2025-04-08 · How we verify

Memantine to Preserve Memory and Neurocognition Following Craniospinal Irradiation- A Randomised Controlled Trial (MEMENTO)

NCT06275035 Phase 3 RECRUITING

The goal of this clinical trial is to evaluate the role of memantine in preservation of memory and neurocognition in patients undergoing craniospinal irradiation. Participants will be randomised into two arms and the interventional arm will receive memantine along with the standard treatment. Researchers will compare the neurocognitive tests of participants in both the arms to see if memantine leads to significant preservation of memory and cognition post radiation therapy.

Details

Lead sponsor	Tata Memorial Centre
Phase	Phase 3
Status	RECRUITING
Enrolment	101
Start date	2024-02-22
Completion	2031-01

Conditions

Neurocognitive Dysfunction

Interventions

Memantine Oral Tablet

Primary outcomes

Cognitive-deterioration-free survival at 2 years — 2 years
Cognitive-deterioration-free survival at 2 years; defined by a drop of 5 points in any of Full Scale Intelligence Quotient (FSIQ), Verbal Intelligence Quotient (VIQ), or Performance Intelligence Quotient (PIQ) compared to baseline (pre-radiation) on Wechsler Adult Intelligence Scale (WAIS), and Wechsler Intelligence Scale for Children (WISC).

Countries

India